Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KMDA - Kamada Ltd


IEX Last Trade
5.75
-0.050   -0.870%

Share volume: 13,113
Last Updated: Fri 30 Aug 2024 09:55:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.80
-0.05
-0.86%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
43%
Profitability 53%
Dept financing 5%
Liquidity 73%
Performance 34%
Company vs Stock growth
vs
Performance
5 Days
0.52%
1 Month
-1.03%
3 Months
10.15%
6 Months
-8.15%
1 Year
2.13%
2 Year
17.35%
Key data
Stock price
$5.75
P/E Ratio 
0.00
DAY RANGE
N/A - $5.79
EPS 
$0.00
52 WEEK RANGE
$4.08 - $6.53
52 WEEK CHANGE
-$0.00
MARKET CAP 
330.474 M
YIELD 
N/A
SHARES OUTSTANDING 
57.474 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$28,947
AVERAGE 30 VOLUME 
$45,561
Company detail
CEO:
Region: US
Website: kamada.com
Employees: 233
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company’s flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor

Recent news